Ping Cao and the value of looking again

Ping Cao reaches for a fishing metaphor when the chemistry gets complicated. Small molecules are bait; different proteins are different fish. Change the bait and you change what you catch. It is an agreeable way to describe specialized research, especially for anyone whose acquaintance with chemistry ended with a school laboratory and a determination never to return.

The comparison also offers a way into Cao’s career. He has spent years developing the tools and teams needed to examine things that are difficult to distinguish. Eventually he helped build a business around that experience. The scale changed from an analytical group inside another company to an organization with its own investors, partners, and choices to make.

Today he is co-founder and CEO of BridGene Biosciences, based in San Jose. The executive title is short. The preparation behind it takes rather longer to explain. It runs through three different academic disciplines, a postdoctoral fellowship, and research leadership at companies that gave him experience of both specialized teams and larger organizations.

A chemist’s long apprenticeship

Cao earned his bachelor’s degree in physical chemistry at Shandong University in Jinan, China. He then completed a master’s in chemical engineering at the SINOPEC Research Institute of Petroleum Processing. His doctorate, in analytical chemistry, came from the University of Texas at Austin. The sequence moved through different ways of working with chemistry: understanding its principles, applying them through engineering, and measuring what is present.

Those degree titles make a useful introduction because they give the later company a technical backstory. Analytical chemistry concerns identification and measurement. It rewards distinctions that can disappear in a less careful account. For an entrepreneur, that is a potentially useful education: the difference between an interesting observation and a dependable result can become the difference between a conversation and a continuing relationship.

After Austin came a postdoctoral fellowship at Genentech. Cao later established a mass spectrometry and analytical group at Tularik. This was already a form of building, with people and instruments assembled around a scientific task. Creating a group means turning an individual area of expertise into something an organization can use. The equipment may occupy a laboratory; its value depends on the work it enables elsewhere.

Amgen acquired Tularik in 2004. At Amgen, Cao led protein characterization within the Discovery Analytical Attributes Group. His team used targeted proteomics alongside genetic research. In plain language, he worked on understanding proteins through their measurable properties. That background connects directly to the experimental methods around which BridGene was organized.

By January 2020, Cao was appearing on the program of the CTIC investment summit in Burlingame as BridGene’s co-founder and CEO. The setting placed his laboratory background in front of an investment audience. His biography emphasized mass spectrometry and proteomics, carrying his technical experience into a new kind of introduction. It is a small, dated glimpse of the transition: the research leader had become a representative of a company among other businesses.

The people around the table

BridGene was founded in 2018. Cao’s fellow co-founder Irene Yuan came with an operations background, including roles at MUFG Union Bank and Redstar Global. Chao Zhang is identified by the company as its scientific founder and scientific advisory board chair. The combination gives the business an origin that extends beyond a single scientist deciding to become an entrepreneur.

Cao brought experience of analytical work and research management. Yuan’s background added another set of organizational skills. Zhang brought his own career in chemistry. Their biographies show several kinds of preparation converging at the same company. A laboratory can produce an observation. Keeping an independent organization working around those observations requires additional disciplines, some of which involve spreadsheets rather than instruments.

Yuan’s formal training also crossed several fields: economics, business administration and law at Nankai University, followed by applied economics and finance at the University of California, Santa Cruz. Those credentials place a different vocabulary beside Cao’s chemistry. Their partnership brings together people trained to examine different parts of the same organization. The research needs to be intelligible to partners; the operating decisions need to make room for research. A co-founder’s biography can help explain why those responsibilities have someone to carry them.

The company’s central platform is called IMTAC, short for Isobaric Mass Tagged Affinity Characterization. The name has the reassuring density of a laboratory label. Its underlying subject is easier to picture: examining how small molecules interact with proteins inside living cells. Cao’s fishing analogy makes the basic problem of selectivity accessible without asking the reader to acquire a new degree.

There is a recognizable continuity here. At Tularik, Cao helped establish analytical capability within a business. At BridGene, analytical capability became a foundation for the business itself. The distinction matters to his personal story. Founding did not erase his earlier specialization; it created a new setting in which that specialization had to support a whole organization.

A reason to come back

One way to follow that organization is through its relationship with Takeda. The companies worked on a pilot in 2020, followed by a collaboration in 2021. A pilot gives two organizations a bounded way to work together. A subsequent agreement extends the relationship. Seen in sequence, these announcements describe something more informative than a single impressive number.

In March 2023, BridGene announced that it had achieved a milestone in the collaboration and was entitled to an undisclosed payment. Another milestone announcement followed that August. The amounts were not the central public detail. The sequence showed work moving through agreed checkpoints, the sort of progress a partnership needs if the initial enthusiasm is to acquire a longer life.

Then, in February 2025, BridGene announced another collaboration and licensing agreement with Takeda. The agreement covered multiple research targets. BridGene would undertake discovery and early development work, with Takeda holding exclusive rights to develop and commercialize resulting products. The division of responsibilities gave each organization a defined part in the arrangement.

The financial language deserves careful reading. The announcement described $46 million in combined upfront and potential early milestone payments, further contingent payments, and eligibility for tiered royalties. The widely reported $770 million figure depended on milestones being met. A potential contract value is a statement about a possible future. It asks the reader to keep the conditions attached.

For Cao, this is an unusually revealing business storyline. Repeat engagements provide a series of occasions on which the company’s work can be evaluated. They also connect his previous experience inside established organizations with his responsibilities at a smaller independent one. The scientist who once supported colleagues’ research now leads a company that other organizations engage to do research with them.

Capital has a calendar

The financing history supplies another set of dates. In May 2021, BridGene announced a $12 million Series A led by Wedo Venture Partners. Kaitai Capital and Takeda Ventures participated alongside existing investor Pangu Venture. The stated plans included expanding the company’s molecular library and enhancing operations. Money arrived with a description of the work it was intended to support.

In July 2022 came a $38.5 million Series B involving Lapam Capital, Junson Capital, and Dyee Capital. The company said it would use the proceeds to develop its platform and advance internal projects. The two rounds recorded a growing pool of resources around the organization Cao led. They also brought more investors into the story, each with a stake in what happened next.

A later $28 million Series B+ was led by Bayland Capital, with participation from GTJA Investment Group, Proxima Ventures, Lapam Capital, and Grains Valley Venture Capital. The public record has a small wrinkle: a corrected release appeared on January 27, 2026, referring to an announcement originally issued on October 16, 2025. The correction concerned an investor description. It would be easy to turn the two dates into two events by reading too quickly.

These numbers describe company financing. They belong beside the operational history because they help explain how an independent research business sustains work over time. The calendar matters as much as the amount: a round creates resources for the next stage, while the next stage still has to be carried out. A press release can be completed considerably faster than a research program.

Choosing the next question

In January 2026, BridGene appointed Bruce Beutler to its scientific advisory board. Beutler, a Nobel laureate and a research leader at UT Southwestern, added another experienced scientific voice around the company. Cao’s announcement connected the appointment to the expertise BridGene wanted for its work. An advisory board is another place where a founder’s judgment becomes visible through the people invited to contribute.

By June 2026, Cao was describing the CEO’s role in terms of choosing research priorities and then executing carefully. He also outlined a company model connecting the Bay Area with a China organization. Those comments bring his career into focus: scientific judgment now operates alongside decisions about people, partnerships, geography, and resources.

“We pick targets with clear biology but challenging chemistry.”

Ping Cao

The sentence captures a preference for questions whose importance is understood even when the practical work remains difficult. It also supplies a fitting place to leave this particular founder. Cao’s career began with acquiring ways to examine the world more closely. It led him to build teams, and then to co-found a company. The next task is to keep choosing questions that make all that preparation useful.